Xtant Medical Holdings, Inc. - 8-K Filing
Xtant Medical reported Q1 2026 revenue of $20.9 million, down from $32.9 million in the same period last year due to asset sales and non-repeating license revenue. The company raised its full-year 2026 revenue guidance to a range of $101-$105 million. It also strengthened its balance sheet by reducing total indebtedness by $13.3 million, entered an exclusive U.S. distribution agreement for Dilon Technologies’ HEMOBLAST® product, and hired Dilon’s U.S. sales team. (Items: 2.02 of this report (including Exhibit 99)
Tickers: $XTNT